Role of Sphingolipid Metabolic Remodeling in Apoptotic and Inflammatory Signaling
Role of Sphingolipid Metabolic Remodeling in Apoptotic and Inflammatory Signaling
Sphingolipid metabolism is not merely a process of membrane-lipid turnover, but an important signaling layer linking death-receptor activation, mitochondrial injury, inflammasome assembly, and cell-fate determination. Under multiple stress and disease contexts, what truly changes is not the isolated increase or decrease of a single sphingolipid species, but the systematic remodeling of the generation, interconversion, compartmental distribution, and receptor coupling relationships among sphingomyelin, ceramide, sphingosine, and sphingosine-1-phosphate. Among these, Fas-, TRAIL-, TNFalpha-, and NLRP3-related pathways most clearly illustrate the mechanistic significance of sphingolipid metabolism shifting from a membrane-structural background to a signal-amplification platform.
Keywords: sphingolipid metabolism; ceramide; Fas; TRAIL; TNFalpha; NLRP3; apoptosis; inflammatory signaling
1 Signaling Basis of Sphingolipid Metabolic Remodeling
1.1 Structural characteristics of the sphingolipid metabolic network
(1) A dynamic metabolic pool rather than a single lipid molecule
The core of the sphingolipid metabolic network is not a single isolated molecule, but a dynamic system composed of sphingomyelin, ceramide, sphingosine, sphingosine-1-phosphate, and certain complex sphingolipids. Its importance lies not only in maintaining membrane structure, but also in providing cells with a rapidly switchable lipid-signaling module through which extracellular stimulation, metabolic stress, and inflammatory input can be converted into distinct cell-fate outputs.
(2) Ceramide as a signal-amplification node
In most apoptosis- and inflammation-related contexts, ceramide occupies the central position in sphingolipid metabolic remodeling. It can be rapidly generated through the sphingomyelinase pathway and can also be continuously supplemented through de novo synthesis and recycling pathways. Its biological significance extends beyond that of a metabolic intermediate, because it can alter membrane microdomain organization, promote receptor clustering, and further influence mitochondria-, lysosome-, and endoplasmic-reticulum-related stress pathways.
1.2 From membrane-lipid background to signaling platform
(1) Formation of ceramide-enriched membrane platforms
Acid sphingomyelinase hydrolyzes sphingomyelin to ceramide, and ceramide has the capacity to promote lateral membrane reorganization and microdomain fusion. The result is not a simple change in membrane-lipid composition, but the formation of ceramide-enriched platforms that favor high-density receptor clustering, thereby allowing originally dispersed transmembrane receptors and downstream signaling proteins to approach one another spatially and undergo coupling more efficiently.
(2) Resetting of signaling-output direction
Sphingolipid metabolic remodeling does not always drive cells unidirectionally toward death, but rather determines which signaling state the cell more readily enters. In general, ceramide accumulation is more commonly associated with amplification of apoptosis, enhancement of inflammation, and mitochondrial injury, whereas sphingosine-1-phosphate more commonly participates in survival, migration, and inflammatory-cell recruitment. However, this distinction should be regarded only as a general framework, because the specific output still depends on chain-length composition, compartmental localization, and receptor background.
2 Sphingolipid Metabolic Remodeling and Death-Receptor Apoptotic Signaling
2.1 The sphingolipid amplification layer in the Fas pathway
(1) Fas receptor activation and DISC assembly
Fas is one of the classical death receptors. After activation by its ligand, it recruits caspase-8 through FADD to form the death-inducing signaling complex, thereby initiating the effector-caspase cascade. Accordingly, whether the Fas pathway can stably enter an apoptotic program depends not only on receptor activation, but also on whether the DISC can be assembled efficiently.
(2) Promotion of membrane platforms by sphingolipid metabolic remodeling
The sphingolipid effect in Fas-related apoptosis is mainly manifested at the membrane-amplification level. Fas stimulation can activate acid sphingomyelinase and promote ceramide generation. Subsequently, local ceramide enrichment drives membrane-platform formation, causing high-density clustering of Fas receptors and creating more favorable spatial conditions for recruitment of FADD and caspase-8.
① Activation of acid sphingomyelinase enhances ceramide generation.
② Ceramide enrichment promotes membrane-microdomain reorganization.
③ Fas receptor clustering and DISC-assembly efficiency thereby increase.
Accordingly, ceramide is not an incidental change outside the Fas pathway, but a structural support layer through which Fas signaling proceeds from receptor activation to amplified apoptosis.
(3) Extension toward the mitochondrial apoptotic layer
The sphingolipid effect in the Fas pathway does not stop at the membrane-receptor level. After caspase-8 activation, Bid can be cleaved to form tBid, which further promotes Bax/Bak-related mitochondrial outer membrane permeabilization. At the same time, ceramide accumulation itself can aggravate mitochondrial membrane injury, reactive oxygen species generation, and cytochrome c release. Thus, death-receptor signaling and the mitochondrial apoptotic amplification loop become further coupled under the background of sphingolipid metabolic remodeling.
2.2 Resetting of sensitivity in the TRAIL pathway
(1) Basic features of the TRAIL receptor pathway
TRAIL is a member of the TNF superfamily and mediates apoptotic signaling mainly through DR4 and DR5. Compared with Fas and TNFalpha, TRAIL has attracted broad attention because of its stronger selectivity toward many tumor cells, but the strength of its effect depends heavily on receptor clustering status and the cellular membrane environment.
(2) DR4/DR5 clustering and ceramide platforms
In the TRAIL pathway, the major role of sphingolipid metabolic remodeling is not simply to increase receptor expression, but to improve the efficiency of receptor-signal assembly. TRAIL stimulation can promote ceramide generation and the formation of ceramide-enriched membrane platforms, which in turn drive DR4/DR5 clustering and make recruitment of FADD and caspase-8 to membrane-proximal signaling complexes more efficient.
(3) Metabolic interpretation of TRAIL sensitivity
What determines whether a cell is sensitive to TRAIL is not only the expression level of DR4/DR5, but also whether the membrane possesses sufficient ceramide platforms to support higher-order receptor clustering. Therefore, sphingolipid metabolic remodeling itself constitutes an important regulatory layer governing the strength of TRAIL responses.
2.3 Branching and redirection in the TNFalpha pathway
(1) TNFalpha signaling is not intrinsically equivalent to cell death
The TNFalpha pathway is mechanistically more complex than Fas and TRAIL. After TNFalpha binds TNFR1, it can either form a membrane-proximal complex biased toward inflammation and survival, or under certain conditions shift toward a death complex containing caspase-8, further inducing apoptosis or even necroptosis. Therefore, the core issue in TNFalpha signaling is not whether it is activated, but whether its output is ultimately directed toward an NF-kappaB-dominated pro-survival program or pushed toward a cell-death program.
(2) Intermediate role of ceramide in the TNFalpha pathway
TNFalpha is one of the classical stimuli that activate sphingolipid metabolism. It can induce sphingomyelin hydrolysis and increase ceramide levels, and the signal can subsequently be further amplified through ceramide-synthesis-related pathways. Thus, ceramide in the TNFalpha pathway is not a single transient signal, but functions more like an intermediate node linking early membrane events with later cell-fate remodeling.
(3) Background of the shift from inflammatory transcription to death amplification
The reason sphingolipid metabolic remodeling is important in the TNFalpha pathway is that it may change the direction of pathway output. On the one hand, TNFalpha itself can trigger NF-kappaB-related pro-inflammatory transcription through TNFR1; on the other hand, sustained ceramide accumulation enhances membrane-microdomain reorganization, mitochondrial stress, and death amplification, making cells more likely to shift from inflammatory responses toward inflammation-associated injury. Therefore, mechanistic analysis of TNFalpha-related tissue injury should not remain at the cytokine level alone, but should incorporate sphingolipid metabolic remodeling as an intermediate amplification layer.
3 Sphingolipid Metabolic Remodeling and the NLRP3 Inflammasome
3.1 Basic structure of the NLRP3 pathway
(1) Two-stage features of priming and assembly
Activation of the NLRP3 inflammasome generally includes two levels: priming and assembly. The former mainly involves upregulation of NLRP3 and pro-inflammatory cytokine precursors, whereas the latter depends on integration of ionic flux changes, mitochondrial injury, lysosomal stress, and related signals, ultimately promoting caspase-1 activation, IL-1beta/IL-18 maturation, and gasdermin D-related pyroptosis.
(2) Why sphingolipid metabolism can intersect with NLRP3
NLRP3 does not directly recognize a single isolated lipid species, but instead tends to integrate organelle damage and cellular stress status. Because sphingolipid metabolic remodeling can simultaneously affect membrane microdomains, lysosomes, mitochondria, and redox status, it is naturally positioned at the upstream signal-integration layer of NLRP3. For this reason, abnormalities in sphingolipid metabolism are often not mere bystanders during NLRP3 activation, but part of the promoting background.
3.2 Coupling mechanisms between ceramide and NLRP3
(1) Promotion of the inflammasome by the ASM-ceramide axis
Recent studies increasingly indicate that the acid sphingomyelinase-ceramide axis can promote activation of the NLRP3 inflammasome. In multiple models, enhancement of acid sphingomyelinase activity, ceramide accumulation, or ceramide-platform formation is often accompanied by stronger NLRP3-related inflammatory output; conversely, inhibition of this axis is frequently associated with weakened inflammasome activation.
(2) Organelle stress and inflammatory amplification
The connection between ceramide and NLRP3 is not confined to the membrane level. More fundamentally, ceramide can promote reactive oxygen species generation, mitochondrial injury, lysosomal dysfunction, and amplification of related stress signals, thereby creating a more favorable intracellular environment for NLRP3 assembly. In other words, the role of sphingolipid metabolic remodeling in the NLRP3 pathway is essentially to translate lipid stress into organelle-damage signals and then further into inflammasome activation.
3.3 Influence of sphingosine-1-phosphate on the priming layer of NLRP3
In contrast to ceramide, which is more strongly biased toward amplification of injury, sphingosine-1-phosphate behaves more as a receptor-coupled inflammatory regulatory molecule in the NLRP3 pathway. It influences not only cell migration and inflammatory-cell recruitment, but also the priming layer of NLRP3 through receptors and their downstream kinase pathways. Thus, sphingolipid metabolic remodeling occurs not only at the inflammasome-assembly layer, but may also be shifted upstream to the transcriptional preparation stage.
4 Bridging Role of Sphingolipids Between Apoptosis and Inflammation
4.1 Death receptors and inflammasomes are not isolated from one another
Fas, TRAIL, TNFalpha, and NLRP3 are often classified separately under the two major themes of apoptosis and inflammation, but under the background of sphingolipid metabolic remodeling these two classes of signals do not exist in parallel isolation. Death receptors can enhance membrane-level signaling through activation of acid sphingomyelinase and formation of ceramide platforms; the mitochondrial and lysosomal damage induced by ceramide can then provide conditions for activation of the NLRP3 inflammasome. In this way, death signals and inflammatory signals become coupled at the lipid level, forming a closed loop of injury, amplification, and further injury.
4.2 Research significance and analytical framework
From a mechanistic perspective, the importance of sphingolipid metabolic remodeling does not lie in proving that ceramide is invariably lethal or that sphingosine-1-phosphate invariably promotes survival, but in revealing a higher-order mode of signal organization: membrane-receptor clustering, organelle stress, and inflammasome assembly can all be linked through the same lipid metabolic network. Establishing an analytical framework centered on Fas, TRAIL, TNFalpha, and NLRP3 helps integrate death-receptor sensitivity, persistence of inflammation, and progression of tissue injury within a unified mechanistic landscape.
5 Enzymatic Stratification and Metabolic Branching of the Sphingolipid Network
5.1 Functional stratification of upstream generation pathways
(1) Rapid-response characteristics of the sphingomyelinase pathway
Under conditions of death-receptor stimulation, oxidative stress, and inflammatory input, the sphingomyelinase pathway usually performs the rapid-generation role for ceramide. Acid sphingomyelinase and neutral sphingomyelinase act in different compartments and membrane environments, allowing sphingomyelin to be converted into ceramide within a relatively short time. Precisely because this process is rapid, local, and structurally linked to membranes, it is more likely to participate in the initiation and amplification of membrane-proximal receptor signaling such as that mediated by Fas, TRAIL, and TNFalpha, rather than merely reflecting downstream metabolic change.
(2) Sustained-remodeling characteristics of the de novo synthesis pathway
In contrast to the sphingomyelinase pathway, the de novo synthesis pathway is more suitable for explaining sustained elevation of the ceramide pool under chronic stress. This pathway begins with serine and palmitoyl-CoA, and gradually forms ceramide through intermediates such as dihydrosphingosine and dihydroceramide. It is more commonly associated with metabolic dysregulation, persistent inflammation, and long-term tissue injury. In other words, the sphingomyelinase pathway behaves more like a short-term response-amplification layer, whereas the de novo synthesis pathway behaves more like a chronic pathological maintenance layer.
5.2 Downstream ceramide branches and signaling divergence
(1) Diversion toward sphingosine and S1P
Ceramide is not the end point of signaling, but the starting point of branch divergence. After cleavage by ceramidase, it yields sphingosine, which can then be converted by sphingosine kinase into sphingosine-1-phosphate. In contrast to ceramide, which is more commonly associated with death amplification and accumulation of injury, S1P more often participates in survival, migration, vascular regulation, and immune-cell recruitment. Thus, diversion of ceramide toward the S1P branch essentially represents a partial shift of the cell from pro-injury output toward pro-adaptive output.
(2) Diversion toward ceramide-1-phosphate and glycosphingolipids
Ceramide can also be further diverted into ceramide-1-phosphate and glycosphingolipid branches. The former is more commonly associated with inflammatory regulation and coordination of membrane signaling, whereas the latter is related to membrane-structural stability, receptor-microdomain composition, and cellular recognition processes. Therefore, sphingolipid metabolic remodeling cannot be summarized simply as "increased ceramide"; one must further determine whether ceramide is being retained, degraded and diverted, or converted into complex sphingolipid branches. Only by separating these branch levels can one truly understand why similar sphingolipid changes lead to different apoptotic and inflammatory outcomes.
5.3 Ceramide synthase isoforms and chain-length specificity
(1) CerS isoforms determine chain-length composition
Different ceramide synthase isoforms preferentially generate ceramides with different chain lengths, meaning that "increased ceramide" is never a single phenotype. Under different stimuli, cells may exhibit profile shifts dominated by C16, C18, or longer-chain ceramides, and this difference is not merely of chemical-structural significance, but is directly related to membrane properties, receptor-clustering capacity, and organelle-response modes.
(2) Chain-length differences determine functional-output differences
Some relatively shorter long-chain ceramides are more readily associated with death-receptor sensitization, membrane-platform formation, and apoptotic amplification, whereas certain longer or very-long-chain species are more strongly biased toward membrane stability and structural maintenance. Therefore, future discussion of the relationship between sphingolipid metabolism and apoptosis or inflammation should treat chain-length stratification as an essential prerequisite rather than ascribing fully identical functions to all ceramides as a single pool.
6 Compartment Specificity and Chain-Length-Dependent Signal Differentiation
6.1 Receptor-assembly background at the plasma membrane
(1) The plasma membrane is the initiation layer for death-receptor amplification
Sphingolipid remodeling at the plasma membrane most directly affects receptor clustering and signal assembly. Fas, DR4, DR5, and certain TNFR1-related complexes all depend on the local membrane environment for efficient assembly. Ceramide enrichment on the plasma-membrane side can increase receptor density, promote adaptor recruitment, and convert originally weak membrane-proximal signaling into highly efficient amplification.
(2) Membrane-platform formation resets the stimulus threshold
The same ligand dose can produce completely different output strengths under different sphingolipid backgrounds. The fundamental reason is that sphingolipid remodeling changes not only membrane composition, but also the conditions under which receptors cross their activation threshold. Therefore, ceramide platforms at the plasma membrane should be regarded as a key prerequisite determining death-receptor sensitivity, rather than as a mere accessory phenomenon after pathway activation.
6.2 Injury and amplification at the mitochondrial level
(1) Mitochondrial ceramide and membrane permeabilization
When sphingolipid metabolic abnormalities extend to the mitochondrial level, the role of ceramide is no longer limited to receptor assembly, but further affects outer-mitochondrial-membrane stability and membrane-permeabilization processes. This enhances reactive oxygen species generation, promotes cytochrome c release, and increases the likelihood that the intrinsic apoptotic program will be initiated.
(2) The mitochondrial level is a point of convergence between apoptosis and inflammation
Mitochondrial injury does not serve only execution of apoptosis. The associated release of ROS and other damage-related signals can also provide conditions for NLRP3 inflammasome assembly. Thus, sphingolipid remodeling at the mitochondrial level possesses the dual significance of an "apoptosis amplifier" and an "upstream inflammatory layer."
6.3 Integration of stress at the endoplasmic reticulum and lysosomal levels
(1) Endoplasmic-reticulum stress and calcium-homeostasis imbalance
Abnormal sphingolipid metabolism can also alter the membrane environment of the endoplasmic reticulum, thereby affecting protein-folding load and calcium homeostasis. When ER stress is superimposed on death-receptor stimulation or TNFalpha input, cells are more likely to shift from transient adaptive responses toward sustained injury.
(2) Altered lysosomal membrane stability
Certain sphingolipid abnormalities are associated with altered lysosomal membrane permeability. Lysosomal damage not only releases proteolytic enzymes that aggravate cellular injury, but also intersects with inflammasome activation. Therefore, promotion of inflammatory output by sphingolipid metabolic remodeling is often the result of multi-compartment integration rather than a single receptor-level event.
7 Sphingolipid Metabolism and Switching of Cell-Death Modes
7.1 Transitional background between apoptosis and pyroptosis
(1) Sphingolipid metabolism can enhance both execution layers
In the classical view, apoptosis and pyroptosis correspond respectively to caspase cascades and the inflammasome execution layer. Under the background of sphingolipid metabolic remodeling, however, these two programs are not always fully separated. Ceramide can enhance both death-receptor and mitochondrial apoptotic signaling, while also driving activation of pyroptosis-related execution pathways through mitochondrial injury, elevated ROS, and NLRP3 presensitization. This means that some cell-death states are fundamentally neither "pure apoptosis" nor "pure pyroptosis," but rather composite injury outputs supported by the same lipid background.
(2) Expansion from receptor apoptosis to inflammatory cell death
When pathways such as Fas, TRAIL, or TNFalpha remain continuously activated and sphingolipid metabolism is maintained in a pro-injury direction, cells often no longer remain in a relatively contained receptor-apoptotic state, but gradually show a tendency toward inflammatory-cytokine maturation, increased membrane injury, and amplified surrounding inflammation. In other words, sphingolipid metabolic remodeling helps drive what would otherwise be a relatively closed apoptotic program toward a more inflammation-propagating death state.
7.2 Potential intersection with necroptosis
(1) Conditions for program switching under a TNFalpha background
The TNFalpha pathway itself possesses the potential to diverge toward necroptosis, and abnormalities in sphingolipid metabolism can further intensify membrane injury, mitochondrial stress, and inflammatory amplification. Therefore, under certain conditions, sphingolipid remodeling may also make cells more likely to switch from a regulated apoptotic program toward a more inflammatory necrotic-like outcome.
(2) Sphingolipid metabolism as a background layer for cell-fate divergence
Mechanistically, sphingolipid metabolism does not independently "determine" a single death mode. Rather, by altering membrane platforms, organelle stress, and inflammatory readiness, it resets the probability of transition among different death pathways. Therefore, when distinguishing the boundaries among apoptosis, pyroptosis, and necroptosis in research design, sphingolipid metabolic status should be incorporated as an upstream variable rather than interpreted only at the terminal execution layer.
8 Pathway Integration in Disease Contexts
8.1 Remodeling of death-receptor sensitivity in the tumor microenvironment
In tumor cells, whether Fas and TRAIL pathways can efficiently trigger apoptosis often depends not only on receptor-expression levels, but also on membrane-microdomain status, ceramide-generation capacity, and the threshold for mitochondrial responsiveness. Accordingly, sphingolipid metabolic remodeling can be regarded as an important intermediate layer for explaining differences in TRAIL sensitivity, Fas resistance, and inconsistent responses to death-receptor-based therapies.
8.2 The TNFalpha-NLRP3 axis in chronic inflammation and metabolic inflammation
Under conditions of chronic inflammation, metabolic inflammation, and sustained tissue injury, TNFalpha input, ceramide accumulation, and NLRP3 activation often form mutually reinforcing relationships. In this context, sphingolipid metabolism is no longer merely a background amplifier of apoptotic signaling, but becomes an integrative layer linking pro-inflammatory transcription, organelle injury, and inflammasome assembly. Therefore, understanding sphingolipid remodeling from the perspective of metabolic inflammation helps connect membrane-lipid abnormalities with persistent inflammatory injury in a more systematic way.
8.3 Translation of danger signals in infection and sterile injury
Whether under infection-related inflammation or sterile injury, cells must translate external danger signals into internal response programs. Sphingolipid metabolic remodeling provides a rapid lipid platform with amplification capacity, allowing death receptors, organelle stress, and inflammasome signaling to be organized within the same framework. Thus, sphingolipid metabolism is better understood as a danger-signal translation platform rather than merely a membrane-lipid background.
9 Related Research Product Tables
9.1 Product table related to sphingolipid metabolic remodeling
Name | CAS No. | Experimental Stage | Key Use | Use Notes |
C2 Ceramide | Modeling of ceramide elevation | Directly increases ceramide signaling burden and constructs a sphingolipid remodeling-apoptosis/inflammation amplification model | Suitable for validation of Fas/TRAIL sensitization, mitochondrial injury, ROS, and caspase activation | |
Ceramide (from chicken egg) | Simulation of endogenous sphingolipid background | Used to supplement a ceramide background closer to natural composition | Suitable for exogenous lipid-complementation or membrane-lipid remodeling experiments; should not be simply equated with short-chain ceramide effects | |
C22 Ceramide | Studies of long-chain ceramide | Used to compare differences among ceramides of different chain lengths in receptor clustering, membrane-platform formation, and apoptotic amplification | Suitable for chain-length-stratified comparison with C2 ceramide | |
Sphingomyelin (from egg yolk) | Upstream substrate layer | Used as an upstream substrate reference for the sphingomyelinase-ceramide axis | Suitable for combined use with sphingomyelinase activity assays and GW4869 inhibition experiments | |
N-Palmitoyl-D-sphingomyelin | Studies of specific sphingomyelin substrates | Used for more focused observation of the relationship between sphingomyelin consumption and ceramide generation | Suitable for experiments on membrane-platform reorganization and lipid-source dissection | |
N-Hexanoyl-D-sphingomyelin | Studies of short-chain sphingomyelin substrates | Used to analyze the effects of substrates with different acyl-chain lengths on sphingomyelin metabolic flux | Can be used in parallel with long-chain sphingomyelin in substrate-selectivity experiments | |
D-erythro-Sphingosine | Modeling of the sphingosine branch | Used to observe the effects of downstream ceramide degradation products on cell death and stress | Suitable for studies of ceramide/sphingosine/S1P balance | |
L-erythro-Sphingosine | Stereochemical control | Used as a stereochemical control molecule in sphingosine-related studies | Suitable for validation of structural specificity of sphingosine-related effects | |
D-erythro-C14-Sphingosine | Acyl-chain-stratified studies | Used to compare the differences among sphingosines of different chain lengths in membrane effects and signaling output | Suitable for structure-function studies of sphingolipid molecules | |
C16-Sphingosine-1-phosphate | Exogenous supplementation of the S1P branch | Directly supplements S1P-like signaling input to observe its effects on the inflammatory priming layer and survival bias | Suitable for paired inhibition-rescue experiments with SPHK inhibitors | |
Fingolimod (FTY720) hydrochloride | Intervention at the S1P-receptor level | Used to validate the extent of involvement of the S1P receptor axis in inflammatory recruitment, survival signaling, and immune regulation | More suitable for receptor-level validation and does not replace inhibition experiments at upstream metabolic-enzyme levels | |
FTY720 (S)-phosphate | Studies of S1P receptor agonism | Used to mimic S1P receptor signaling output under the active phosphorylated state of FTY720 | Suitable for studies of biased signaling at the S1P-receptor level | |
ABC294640 | Inhibition of S1P generation | As a sphingosine kinase 2 inhibitor, used to analyze the role of the S1P branch in inflammatory transcription and cell survival | Suitable for combined use with exogenous S1P rescue experiments | |
N-Lauroyl ceramide-1-phosphate (ammonium salt) | Studies of the ceramide-1-phosphate branch | Used to analyze how further phosphorylation of ceramide regulates inflammation and membrane signaling | Suitable for functional distinction between the C1P branch and the ceramide branch | |
N-Octanoyl ceramide-1-phosphate (ammonium salt) | Studies of short-chain C1P | Convenient for construction of ceramide-1-phosphate supplementation models | Can be compared in parallel with long-chain C1P molecules to examine differences in inflammatory regulation | |
alpha-Galactosylceramide | Expanded studies of immune sphingolipids | Used to extend the mechanistic connection between sphingolipid metabolism, immune activation, and inflammatory amplification | More suitable for studies of immune regulation and inflammation-cross-talk mechanisms | |
Glucosylceramide synthase inhibitor-IN-2 | Blockade of the glycosphingolipid branch | Used to analyze how diversion of ceramide into the glycosphingolipid branch affects death/inflammatory output | Suitable for combined use with ceramide-accumulation readouts | |
Glucosylceramide synthase inhibitor-IN-4 | Blockade of the glycosphingolipid branch | Used for further dissection of the role of the glycosphingolipid-generating branch in membrane-receptor signaling | Suitable for mechanistic confirmation or alternative inhibition validation | |
MCC950 | NLRP3 blockade | A classical NLRP3 inhibitor used to confirm whether IL-1beta release and caspase-1 activation after sphingolipid remodeling depend on NLRP3 | Suitable for use at the NLRP3 validation layer | |
CY-09 | NLRP3 blockade | Used to validate NLRP3-dependent inflammatory output from the perspective of a different inhibitor | Suitable for cross-validation with MCC950 | |
Belnacasan (VX-765) | Inhibition at the inflammatory execution layer | As a caspase-1-related inhibitory tool, used to distinguish inflammasome assembly from the downstream inflammatory execution layer | Suitable for combination with MCC950/Nigericin | |
VRT-043198 | Inhibition of the caspase-1 subfamily | Used to validate caspase-1/caspase-4-related steps more proximally to the inflammatory execution end | Suitable for use before and after detection of pyroptosis and IL-1beta maturation | |
Nigericin sodium salt ready-to-use solution | NLRP3 activation | Used as a classical second-signal stimulus for establishment of inflammasome-assembly models | Suitable for use with LPS priming | |
CP-424174 | IL-1beta/NLRP3-related validation | Used to assist validation of NLRP3-related inflammatory output from the level of IL-1beta post-processing | More suitable as a supplementary validation tool and does not replace classical NLRP3 inhibitors |
9.2 Product table related to Fas, TRAIL, TNFalpha, and NLRP3 pathways
Catalog No. | Name | Grade and Purity | Research Direction / Intended Use |
Sphingomyelinase | Bioactive, recombinant, ActiBioPure™, high performance, EnzymoPure™, ≥90%(SDS-PAGE), ≥200 U/mg enzyme powder | Acts directly on the sphingomyelin-ceramide axis and is suitable for constructing sphingolipid metabolic remodeling models, as well as for validating the effects of enhanced ceramide generation on Fas/TRAIL apoptotic sensitivity and NLRP3 inflammatory amplification | |
Sphingomyelinase (Staphylococcus aureus) | EnzymoPure™, liquid formulation | Suitable for exogenous sphingomyelin-hydrolysis stimulation to rapidly increase ceramide-generation pressure and to observe changes in membrane-platform formation, death-receptor clustering, and inflammatory activation | |
Mouse Sphingomyelin Phosphodiesterase 2 (NSMASE) ELISA Kit | BioReagent | Suitable for detection of changes related to upstream enzyme activity in sphingolipid metabolism and for strengthening the evidence chain for whether sphingolipid remodeling has occurred, especially in mouse cell or animal systems | |
Fas ligand | Moligand™ | Used for direct activation of the Fas pathway to construct death-receptor-induced apoptosis models, and suitable for combination with sphingomyelinase/ceramide-manipulation experiments to validate the role of membrane-lipid remodeling in amplification of Fas signaling | |
Recombinant Human Fas/TNFRSF6/CD95 Protein | Animal-free, carrier-free, Bioactive, ActiBioPure™, His Tag, ≥95%(SDS-PAGE) | Suitable for Fas-receptor binding, competition, or mechanistic validation experiments, and also suitable for receptor-level interaction studies related to Fas membrane-platform reorganization and DISC assembly | |
Fas Antibody | Carrier-free, ExactAb™, validated, high performance, see COA | Suitable for analysis of Fas receptor expression, localization, and pathway responses, and can be used in Western blotting, flow cytometry, and immunostaining | |
Fas Ligand/CD178 Armenian hamster mAb | Carrier-free, azide-free, validated, ≥95%(SDS-PAGE), see COA | Suitable for FasL detection or blocking validation, and can be paired with Fas-ligand stimulation experiments to distinguish receptor activation from changes in ligand source | |
Bioymifi | ≥97%(HPLC) | Acts directly on DR5 and is suitable for constructing TRAIL death-receptor activation models and for validating whether sphingolipid metabolic remodeling enhances TRAIL-receptor clustering and apoptotic output | |
Recombinant Human TRAIL/TNFSF10 Protein | Carrier-free, Bioactive, high performance, His Tag, ≥95%(SDS-PAGE) | Used for TRAIL-pathway stimulation and suitable for assessing TRAIL sensitivity, caspase-8 activation, and receptor-level signal amplification under sphingolipid-remodeled conditions | |
Recombinant Human TRAIL R2/TNFRSF10B Protein | ActiBioPure™, Bioactive, animal-free, carrier-free, azide-free, ≥97%(SDS-PAGE&HPLC) | Suitable for TRAIL-R2/DR5 receptor-binding, competition, and mechanistic studies, especially in connection with the theme of TRAIL-DR5 clustering | |
Recombinant Human TNF-α Protein | Animal-free, carrier-free, Bioactive, ActiBioPure™, high performance, His Tag, ≥95%(SDS-PAGE), see COA | Used to construct TNFalpha stimulation models and to analyze inflammatory transcription, death-signal branching, and the regulatory role of sphingolipid metabolic remodeling in the direction of TNFalpha output | |
Bay 11-7085 | ≥98%(HPLC) | As an irreversible inhibitor of TNF-alpha-induced IkappaBalpha phosphorylation, suitable for dissecting the relative contributions of the NF-kappaB pro-inflammatory branch and the death/injury branch in the TNFalpha pathway | |
R 7050 | ≥99% | Suitable for receptor-level blockade of TNFalpha signaling and for validating whether sphingolipid metabolic changes depend on upstream TNFR-mediated input | |
Recombinant Human NLRP3 Protein | Carrier-free, His Tag, ≥90%(SDS-PAGE) | Suitable for NLRP3 target validation, protein-interaction studies, or in vitro mechanistic experiments, providing more direct evidence at the inflammasome level | |
α-Glucosidase/NLRP3-IN-1 |
| Suitable for validation of NLRP3 dependence and for determining whether IL-1beta release and caspase-1 activation after sphingolipid remodeling represent NLRP3-mediated inflammatory output | |
Lipopolysaccharides |
| Suitable for priming treatment in the initiation stage of the NLRP3 inflammasome and aligns with two-stage inflammasome model design involving priming and assembly | |
Human NLR Family, Pyrin Domain Containing Protein 3 (NALP3/NLRP3) ELISA Kit | BioReagent | Suitable for detection of changes in NLRP3 expression and for evaluating inflammasome-related expression levels after sphingolipid metabolic remodeling, TNFalpha stimulation, or death-receptor amplification | |
Human Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Suitable for detection of inflammatory-output changes and for quantitative validation in experiments involving TNFalpha stimulation, NLRP3 amplification, and sphingolipid-metabolism manipulation |
The role of sphingolipid metabolic remodeling in apoptotic and inflammatory signaling has clearly extended beyond the traditional concept of a merely supportive membrane-lipid layer. It can enhance Fas- and TRAIL-related death-receptor clustering through ceramide-enriched platforms, influence branching between inflammatory and death outputs in the TNFalpha pathway, and further promote NLRP3 inflammasome activation through organelle stress.